+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2015

  • ID: 3308771
  • Report
  • June 2015
  • 94 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Advinus Therapeutics Ltd.
  • iCo Therapeutics Inc.
  • Merck KGaA
  • Mologen AG
  • Nanomerics Ltd
  • Sanofi
  • MORE
Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2015

Summary

This, ‘Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2015’, provides an overview of the Leishmaniasis (Kala-Azar)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Leishmaniasis (Kala-Azar) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Leishmaniasis (Kala-Azar) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Leishmaniasis (Kala-Azar) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • Advinus Therapeutics Ltd.
  • iCo Therapeutics Inc.
  • Merck KGaA
  • Mologen AG
  • Nanomerics Ltd
  • Sanofi
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Leishmaniasis (Kala-Azar) Overview
Therapeutics Development
Pipeline Products for Leishmaniasis (Kala-Azar) - Overview
Pipeline Products for Leishmaniasis (Kala-Azar) - Comparative Analysis
Leishmaniasis (Kala-Azar) - Therapeutics under Development by Companies
Leishmaniasis (Kala-Azar) - Therapeutics under Investigation by Universities/Institutes
Leishmaniasis (Kala-Azar) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Leishmaniasis (Kala-Azar) - Products under Development by Companies
Leishmaniasis (Kala-Azar) - Products under Investigation by Universities/Institutes
Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development
Advinus Therapeutics Ltd.
Anacor Pharmaceuticals, Inc.
Dafra Pharma International Ltd.
Georgia Tech Research Corporation
iCo Therapeutics Inc.
Merck KGaA
Mologen AG
Nanomerics Ltd
Sanofi
Takeda Pharmaceutical Company Limited
Zydus Cadila Healthcare Limited
Leishmaniasis (Kala-Azar) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
amphotericin b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amphotericin b NanoDisk - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AS-605240 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CDRI-99/288 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
corifungin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug to Inhibit PDE for Leishmaniasis and Trypanosomiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fexinidazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Indotecan hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KVH-14 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
leishmaniasis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
leishmaniasis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
leishmaniasis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methoxycoronaridine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGN-1331 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NPC-1161B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oleylphosphocholine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegylated amphotericin B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-010269 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Visceral Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Infectious Disease and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Protozoal Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Visceral Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Block LHR1 for Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VGP-106 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
visceral leishmaniasis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VL-2098 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leishmaniasis (Kala-Azar) - Recent Pipeline Updates
Leishmaniasis (Kala-Azar) - Dormant Projects
Leishmaniasis (Kala-Azar) - Discontinued Products
Leishmaniasis (Kala-Azar) - Product Development Milestones
Featured News & Press Releases
Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions
Nov 03, 2014: Presentation of DNA vaccine against leishmaniasis at IMED 2014
Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients
Mar 19, 2014: Knight Therapeutics Announces FDA Approval for Impavido (Miltefosine) for the Treatment of Visceral, Mucosal and Cutaneous Leishmaniasis
Nov 11, 2013: Paladin Announces Extension of the Impavido® PDUFA Date by Three Months
Jun 19, 2013: Paladin Receives Priority Review Status From FDA For Impavido NDA Submission For Treatment Of Leishmaniasis
Dec 17, 2012: PATH’s Drug Development Program Announces Successful Completion Of Phase IIIb Clinical Trial Of Paromomycin Intramuscular Injection In Bangladesh
Jun 26, 2012: Leishdnavax Consortium Successfully Concludes Preclinical Development Of MGN1331 DNA Vaccine Against Leishmaniasis
Mar 06, 2012: £10 million boost for neglected tropical disease research at Dundee
Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2015
Number of Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Advinus Therapeutics Ltd., H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Dafra Pharma International Ltd., H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Georgia Tech Research Corporation, H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc., H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Merck KGaA, H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Mologen AG, H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Sanofi, H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Zydus Cadila Healthcare Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Leishmaniasis (Kala-Azar) Therapeutics - Recent Pipeline Updates, H1 2015
Leishmaniasis (Kala-Azar) - Dormant Projects, H1 2015
Leishmaniasis (Kala-Azar) - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2015
Number of Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
4 of 5
Advinus Therapeutics Ltd.
Anacor Pharmaceuticals, Inc.
Dafra Pharma International Ltd.
Georgia Tech Research Corporation
iCo Therapeutics Inc.
Merck KGaA
Mologen AG
Nanomerics Ltd
Sanofi
Takeda Pharmaceutical Company Limited
Zydus Cadila Healthcare Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll